|
1) 金沢大学 血液内科・呼吸器内科. 血液・呼吸器内科のお役立ち情報. 記事カテゴリ｢播種性血管内凝固症候群 (DIC) (図解)｣http://www.3nai.jp/weblog/archive/category3932.html
|
|
|
|
|
2) Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341: 586-92
|
|
|
|
|
3) Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med. 2004; 32: S293-7
|
|
|
|
|
|
4) Pawlinski R, Pedersen B, Mackman N, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004; 103: 1342-7
|
|
|
|
|
|
5) Huerta-Zepeda A, Cabello-Gutiérrez C, Ruiz-Ordaz BH, et al. Crosstalk between coagulation and inflammation during Dengue virus infection. Thromb Haemost. 2008; 99: 936-43
|
|
|
|
|
|
6) Niessen F, Schaffner F, Furlan-Freguia C, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature. 2008; 452: 654-8
|
|
|
|
|
|
7) Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010; 38 (2 Suppl): S26-34
|
|
|
|
|
|
8) Asakura H, Ontachi Y, Nakao S, et al. Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in LPS-induced DIC in rats. Crit Care Med. 2006; 34: 2421-5
|
|
|
|
|
|
9) Ontachi Y, Asakura H, Nakao S, et al. No interplay between the pathways mediating coagulation and inflammation in tissue factor-induced disseminated intravascular coagulation in rats. Crit Care Med. 2006; 34: 2646-50
|
|
|
|
|
|
10) Weiler H. Regulation of inflammation by the protein C system. Crit Care Med. 2010; 38 (2 Suppl): S18-25
|
|
|
|
|
|
11) Sarangi PP, Lee HW, Kim M. Activated protein C action in inflammation. Br J Haematol. 2010; 148: 817-33
|
|
|
|
|
|
12) Toltl LJ, Beaudin S, Liaw PC. Activated protein C up-regulates IL-10 and inhibits tissue factor in blood monocytes. J Immunol. 2008; 181: 2165-73
|
|
|
|
|
|
13) Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007; 204: 2439-48
|
|
|
|
|
|
14) van Veen SQ, Levi M, van Vliet AK, et al. Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis. Crit Care Med. 2006; 34: 2799-805
|
|
|
|
|
|
15) Choi G, Hofstra JJ, Roelofs JJ, et al. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med. 2007; 35: 1362-8
|
|
|
|
|
|
16) Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344: 699-709
|
|
|
|
|
|
17) Fumagalli R, Mignini MA. The safety profile of drotrecogin alfa (activated). Crit Care. 2007; 11 Suppl 5: S6
|
|
|
|
|
|
18) Ely EW, Laterre PF, Angus DC. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003; 31: 12-9
|
|
|
|
|
|
19) Warren HS, Suffredini AF, Eichacker PQ, et al. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med. 2002; 347: 1027-30
|
|
|
|
|
|
20) Poole D, Bertolini G, Garattini S. Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. Lancet Infect Dis. 2009; 9: 67-72
|
|
|
|
|
|
21) Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005; 353: 1332-41
|
|
|
|
|
|
22) Nadel S, Goldstein B, Williams MD. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007; 369: 836-43
|
|
|
|
|
|
23) Carlet J. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Crit Care Med. 2006; 34: 525-9
|
|
|
|
|
|
24) Dellinger RP, Carlet JM, Masur H. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2004; 30: 536-55
|
|
|
|
|
|
25) Warren BL, Eid A, Singer P, Pillay SS, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001; 286: 1869-78
|
|
|
|
|
|
26) Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003; 290: 238-47
|
|
|
|
|
|
27) Toussaint S, Gerlach H. Activated protein C for sepsis. N Engl J Med. 2009; 361: 2646-52
|
|
|
|
|
|
28) Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009; 15: 1318-21
|
|
|
|
|
|
29) Mosnier LO, Zampolli A, Kerschen EJ, et al. Hyperantithrombotic, noncytoprotective Glu149 Ala-activated protein C mutant. Blood. 2009; 113: 5970-8
|
|
|
|
|
|
30) Xu J, Ji Y, Zhang X, et al. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. J Thromb Haemost. 2009; 7: 851-6
|
|
|
|
|
|
31) Niessen F, Furlan-Freguia C, Fernández JA, et al. Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood. 2009; 113: 2859-66
|
|
|
|
|
|
32) Isobe H, Okajima K, Uchiba M, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation. 2001; 104: 1171-5
|
|
|
|
|
|
33) Van Sluis GL, Niers TM, Esmon CT, et al. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood. 2009; 114: 1968-73
|
|
|
|
|
|
34) Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. 2004; 104: 3878-85
|
|
|
|
|
|
35) Andonegui G, Bonder CS, Green F, et al. Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest. 2003; 111: 1011-20
|
|
|
|
|
|
36) Monnet X, Lamia B, Anguel N, et al. Rapid and beneficial hemodynamic effects of activated protein C in septic shock patients. Intensive Care Med. 2005; 31: 1573-6
|
|
|
|
|
|
37) Kalil AC, Coyle SM, Um JY, et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock. 2004; 21: 222-9
|
|
|
|
|
|
38) Sturn DH, Kaneider NC, Feistritzer C, et al. Expression and function of the endothelial protein C receptor in human neutrophils. Blood. 2003; 102: 1499-505
|
|
|
|
|
|
39) Pereira C, Schaer DJ, Bachli EB, et al. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008; 28: 504-10
|
|
|
|
|
|
40) Kerschen E, Hernandez I, Zogg M, et al. Activated protein C targets CD8＋ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest. 2010; 120: 3167-78
|
|
|
|
|
|
41) Messaris E, Betrosian AP, Memos N, et al. Administration of human protein C improves survival in an experimental model of sepsis. Crit Care Med. 2010; 38: 209-16
|
|
|
|
|
|
42) Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood. 2010; 115: 1121-30
|
|
|
|
|